Rapport Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Rapport Therapeutics, Inc. (RAPP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.16 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 222.12K shares, a 54.91% decline year-over-year.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.94M shares, a 18.90% increase year-over-year.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 126.80K shares, a 43.50% decline year-over-year.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 273.14K shares, a 46.69% increase year-over-year.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.52M shares, a 12.10% decline from fiscal 2024.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.87M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 222.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 2.16M shares 10-Q · filed 2026-08-05 | 2.29M shares derived: sum of 3 quarters · filed 2026-08-05 | 2.56M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 1.94M shares 10-Q · filed 2026-05-07 | 2.06M shares derived: sum of 2 quarters · filed 2026-05-07 | 2.34M shares derived: sum of 3 quarters · filed 2026-05-07 | 2.83M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 126.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 399.94K shares derived: sum of 2 quarters · filed 2026-03-10 | 892.54K shares derived: sum of 3 quarters · filed 2026-03-10 | 2.52M shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 273.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 765.74K shares derived: sum of 2 quarters · filed 2025-11-06 | 2.40M shares 10-Q · filed 2025-11-06 | 2.62M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 492.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 2.12M shares 10-Q · filed 2025-08-07 | 2.35M shares derived: sum of 3 quarters · filed 2025-08-07 | 2.53M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 1.63M shares 10-Q · filed 2025-05-08 | 1.85M shares derived: sum of 2 quarters · filed 2025-05-08 | 2.04M shares derived: sum of 3 quarters · filed 2025-05-08 | |
| 2024-12-31 | 224.42K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 410.62K shares derived: sum of 2 quarters · filed 2025-03-11 | 2.87M shares 10-K · filed 2025-03-11 | |
| 2024-09-30 | 186.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 2.65M shares 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | 2.46M shares 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |